Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175

Shortened current direct-acting antiviral (DAA) therapies while less expensive, have not provided satisfactory efficacy in naïve cirrhotics, treatment experienced non-cirrhotics or even genotype-3 (GT3)-infected patients. Since DAA regimens consist of the same classes of inhibitors—NS5A (NS5Ai) and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Gallay, Philippe A., Chatterji, Udayan, Bobardt, Michael D., Long, Zhengyu, Zhang, Shengli, Su, Zhuang
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841536/
https://ncbi.nlm.nih.gov/pubmed/27104614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0152036
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires